Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Biogen Inc patents


Recent patent applications related to Biogen Inc. Biogen Inc is listed as an Agent/Assignee. Note: Biogen Inc may have other listings under different names/spellings. We're not affiliated with Biogen Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Biogen Inc-related inventors


Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Inc

Methods of treating progressive forms of multiple sclerosis

The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis.. . ... Biogen Inc

Treatment of diffuse large-cell lymphoma with anti-cd20 antibody

The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-cd20 antibody and chemotherapy. Particular embodiments include the administration of anti-cd20 antibody in combination with chemotherapy comprising chop (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.. ... Biogen Inc

Biaryl inhibitors of bruton's tyrosine kinase

The present invention provides compounds and compositions thereof which are useful as inhibitors of bruton's tyrosine kinase and which exhibit desirable characteristics for the same.. . ... Biogen Inc

Methods and products for evaluating an immune response to a therapeutic protein

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a vla4 binding antibody (e.g., natalizumab).. ... Biogen Inc

Anti-tnf-alpha polypeptide composition and use thereof

The invention provides a composition comprising an anti-tumor necrosis factor (tnf)-alpha polypeptide, wherein the composition produces a reduced level of immunogenicity when administered to a subject, as well as a treatment method involving the administration of the composition.. . ... Biogen Inc

Bruton's tyrosine kinase inhibitors

The present invention provides compounds useful as inhibitors of btk, compositions thereof, and methods of using the same.. . ... Biogen Inc

Methods for evaluating patients

Methods for evaluating subjects having conditions associated with loss of muscle function (e.g., a motor neuron disease, a neuromuscular disease, or a myopathy) by measuring muscle function (e.g., muscle strength) are disclosed.. . ... Biogen Inc

Methods and compositions for detecting therapeutic nucleic acids

The present disclosure relates, in some aspects, to the field of nucleic acid detection. Disclosed herein are methods and compositions for detecting nucleic acids using synthetic single-stranded ribonucleic acids (rnas). ... Biogen Inc

S1p modulating agents

Compounds of formula (i) or (ii) can modulate the activity of s1p receptors.. . ... Biogen Inc

Biogen Ma Inc.

. . ... Biogen Inc

Method and composition to increase radiation-induced tumor therapeutic effects

Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory asmase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. Asmase levels are increased in tumor endothelium by administration of a recombinant dna construct comprising a region coding for a functional asmase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of asmase.. ... Biogen Inc

Method and composition to increase radiation-induced tumor therapeutic effects

Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory asmase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. Asmase levels are increased in tumor endothelium by administration of a recombinant dna construct comprising a region coding for a functional asmase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of asmase.. ... Biogen Inc

Methods for improved measurements of brain volume and changes in brain volume

Methods of the disclosure may include obtaining a first set of medical images at a first time point and a second set of medical images at a second time point, each set including at least two medical images. First and second algorithms may be used to calculate, respectively, first and third brain volume (bv) values at the first time point based on two or more images from the first set of medical images and second and fourth bv values at the second time point based on two or more images from the second set of medical images. ... Biogen Inc

01/11/18 / #20180011112

Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain

This disclosure relates to the use of anti-α-synuclein antibody to diagnose an elevated level of α-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels of α-synuclein in a blood plasma or csf following administration to the test subject of an anti-α-synuclein antibody or antigen-binding fragment thereof, which can bind α-synuclein with sufficient activity to alter the net efflux of α-synuclein from brain to blood, or from brain to csf.. ... Biogen Inc

01/04/18 / #20180002356

Heterobicyclic sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Inc

01/04/18 / #20180000770

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.. ... Biogen Inc

12/28/17 / #20170369560

Human anti-tau antibodies

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. ... Biogen Inc

12/28/17 / #20170369516

Oxidized lipids and methods of use thereof

The present invention is directed to oxidized lipids and pharmaceutical compositions comprising the same. The present invention is also directed to methods of making an oxidized lipid of the invention and to methods of treating or preventing fibrosis or inflammatory diseases or disorders comprising an oxidized lipid of the invention.. ... Biogen Inc

12/28/17 / #20170368013

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.. ... Biogen Inc

12/21/17 / #20170363643

Compositions and methods for detection of smn protein in a subject and treatment of a subject

Disclosed herein are compounds, compositions and methods for modulating splicing of smn2 mrna in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. ... Biogen Inc

12/21/17 / #20170362324

Humanized anti-alpha v beta 5 antibodies and uses thereof

Humanized antibodies and antibody fragments that bind to αvβ5 are disclosed. Also disclosed are methods of using the disclosed antibodies and antibody fragments to treat or prevent αvβ5-mediated diseases.. ... Biogen Inc

12/21/17 / #20170360890

Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

The present invention provides a method for treating multiple sclerosis (ms), and for reducing flu-like symptoms associated with administration of an interferon to a patient with ms. The method involves intramuscularly administering the interferon to the ms patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. ... Biogen Inc

12/21/17 / #20170360699

Apparatus for compound dispersion

Methods and apparatuses for dispersing a compound within the patient are described. In one embodiment, an effective amount of a compound may be present in the cerebrospinal fluid of a patient and a force may be applied to the torso of the patient sufficient to enhance the convection of the cerebrospinal fluid. ... Biogen Inc

12/14/17 / #20170355771

Anti-gpiib/iiia antibodies and uses thereof

Antibodies and antibody fragments that specifically bind to glycoprotein iib/iiia (gpiib/iiia) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. ... Biogen Inc

12/14/17 / #20170355729

Methods and compositions for controlling antibody aggregation

Disclosed herein are methods of purifying monoclonal antibodies and related compositions.. . ... Biogen Inc

12/14/17 / #20170354746

Methods of inducing responsiveness to anti-angiogenic agent

The invention provides methods of inducing or improving responsiveness to a vegf antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a f as-chimera gene operably linked to an endothelial cell-specific promoter and administering the vegf antagonist.. . ... Biogen Inc

12/14/17 / #20170354639

Diterpenoid derivatives and methods of use thereof

Provided herein are compounds of formula (i) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with nrf2/nf-κb pathways. ... Biogen Inc

12/14/17 / #20170354630

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.. ... Biogen Inc

12/07/17 / #20170348227

Methods of intravenous administration of glyburide

The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.. . ... Biogen Inc

11/30/17 / #20170342152

Anti-glycoprotein iib/iiia antibodies

Antibodies and antigen-binding antibody fragments that bind to gpiib/iiia and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind gpiib/iiia on activated platelets while others do not show a preference for binding gpiib/iiia on resting versus activated platelets. ... Biogen Inc

11/23/17 / #20170335000

Antibodies to vla-1

Antibodies that specifically bind to vla-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by vla-1 antibodies and their ligands, and vla-1 antagonists and agonists identified by using the structure coordinates of these structures.. ... Biogen Inc

11/23/17 / #20170333340

Methods of intravenous administration of glyburide

The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.. . ... Biogen Inc

11/16/17 / #20170327861

Copper supplementation for control of glycosylation in mammalian cell culture process

The present invention pertains to a cell culture medium comprising copper as a media supplement, which was shown to control recombinant protein glycosylation and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.. ... Biogen Inc

11/16/17 / #20170327786

Hypotaurine, gaba, beta-alanine, and choline for control of waste byproduct accumulation in mammalian cell culture process

The present invention pertains to a cell culture medium comprising hypotaurine, gaba, and/or beta-alanine or the combination of choline and hypotaurine, gaba, and/or beta-alanine as media supplements which is shown to control viability, growth, and waste byproduct accumulation. The present invention further pertains to a method of producing a polypeptide of interest in a large scale cell culture containing hypotaurine, gaba, and/or beta-alanine or the combination of choline and hypotaurine, gaba, and/or beta-alanine.. ... Biogen Inc

10/26/17 / #20170306402

Systems and methods for characterization of multiple sclerosis

Methods and systems to characterize multiple sclerosis (ms) in a subject, e.g., in a subject having a progressive form of ms are disclosed.. . ... Biogen Inc

10/26/17 / #20170306026

Administration of agents for the treatment of inflammation

A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.. ... Biogen Inc

10/12/17 / #20170290990

Injector lockout prevention device

A device that prevents the accidental activation and lockout of an autoinjector. In illustrative embodiments, a resistance unit is configured to resist deployment of the needle until a critical force is applied by the user to the autoinjector, at which point, the resistance of the resistance unit is overcome. ... Biogen Inc

09/28/17 / #20170276659

Systems and methods for assessing therapeutic proteins

Systems and methods for assessing the oxidation status of a pharmaceutical preparations are provided herein. Methods provided herein are particularly useful for assessing pharmaceutical preparations comprising therapeutic proteins (e.g., therapeutic antibodies).. ... Biogen Inc

09/14/17 / #20170260516

Optimized factor ix gene

The present invention provides codon optimized factor ix sequences, vectors and host cells comprising codon optimized factor ix sequences, polypeptides encoded by codon optimized factor ix sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized factor ix nucleic acid sequence or the polypeptide encoded thereby.. ... Biogen Inc

09/14/17 / #20170258818

Oxidized lipids and treatment or prevention of fibrosis

The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same.. . ... Biogen Inc

08/31/17 / #20170247655

Methods of preventing and removing trisulfide bonds

The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. ... Biogen Inc

08/31/17 / #20170247457

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. ... Biogen Inc

08/31/17 / #20170246197

High-purity phospholipids

Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. ... Biogen Inc

08/24/17 / #20170239280

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Inc

08/17/17 / #20170233485

Anti-cd40 antibodies and uses thereof

Antibodies and antibody fragments that bind to human cd40 and inhibit interaction between cd40 and its ligand, cd40l are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit hyperactivation of b or t cells and treat or prevent disorders such as autoimmune diseases.. ... Biogen Inc

08/17/17 / #20170232111

Pegylation method

The present invention relates to a method for pegylating interferon beta.. . ... Biogen Inc

08/03/17 / #20170216434

Compositions and methods for treatment of sickle cell disease

This invention relates to methods of treating sickle cell disease with vla-4 antagonists and methods for evaluating the responsiveness of patients having sickle cell disease to treatment with vla-4 antagonists.. . ... Biogen Inc

07/27/17 / #20170209529

Fc receptor (fcrn) binding peptides and uses thereof

The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal fc receptor (fcrn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. ... Biogen Inc

07/20/17 / #20170204093

Irak4 inhibiting agents

Provided are compounds of formula (i), or pharmaceutically acceptable salts thereof, and methods for their use and production.. . ... Biogen Inc

07/20/17 / #20170202743

Medical metering device

A metering device that improves the aseptic transfer of powder and reconstitution fluid into the metering device for medical use. In some implementations, the metering device comprises a housing, containing a metering chamber that defines a volume. ... Biogen Inc

07/13/17 / #20170197960

Atx modulating agents

Compounds of formula (i) can modulate the activity of autotaxin (atx).. . ... Biogen Inc

06/29/17 / #the present invention provides compounds of formula (i) and (ii):

Biogen Ma Inc.

. . ... Biogen Inc

06/22/17 / #20170174710

Compounds that are s1p modulating agents and/or atx modulating agents

Compounds of formula (i) can modulate the activity of one or more s1p receptors and/or the activity of autotaxin (atx).. . ... Biogen Inc

06/22/17 / #20170173122

Lyophilized factor ix formulations

The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a factor ix (fix) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a fix polypeptide. ... Biogen Inc

06/08/17 / #20170158687

Atx modulating agents

Disclosed are bicyclic aryl compounds of formula (i), that can modulate the activity of the autotaxin (atx) enzyme. This invention further relates to compounds that are atx inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.. ... Biogen Inc

05/11/17 / #20170130186

Cross-scale modeling of bioreactor cultures using raman spectroscopy

Aspect of the disclosure relate to methods of assessing a bioreactor culture that involve determining a culture parameter of the manufacturing-scale bioreactor culture using a model that relates a raman spectrum to the culture parameter. Related bioreactor system are also provided.. ... Biogen Inc

04/27/17 / #20170114382

Methods of increasing protein production in mammalian cells

Aspects of the present disclosure provide compositions and methods for increasing protein production in mammalian cells, e.g. Methods of increasing mammalian cell expression of a protein of interest, comprising culturing mammalian cells that overexpress a protein of interest and are modified to overexpress a gene encoding rab 11 or yap1, as well as mammalian cells that overexpress a protein of interest and which are modified to overexpress a gene encoding rab 11 or yap1.. ... Biogen Inc

04/20/17 / #20170107554

Method for producing astaxanthin

A method for increasing efficiency of a method for producing astaxanthin by culturing a microalga. A method for producing astaxanthin in which astaxanthin is produced in an algal body by culturing a microalga, wherein photoirradiation is performed using both a blue led of peak wavelength from 420 to 500 nm and a red led of peak wavelength from 620 to 690 nm, at least during an astaxanthin-producing culturing phase of a culturing period. ... Biogen Inc

03/30/17 / #20170086763

Wearable medical detector

Various embodiments of medical detector systems as well as their methods of operation are disclosed. In one embodiment, one or more detectors are coupled to wearable structures for detecting at least a first tracer within a body portion. ... Biogen Inc

03/30/17 / #20170086555

Space-saving suitcase handle assemblies

A space-saving suitcase assembly comprising a plurality of telescoping tubes, the plurality of telescoping tubes including a base tube and a top tube; a handle connected to the top tube; a release button positioned on the handle; the suitcase having a top side, a front side, a back side, a left side, a right side, and a bottom side creating a perimeter surface and an internal volume, a modular stabilizing element made from a rigid material, the modular stabilizing element affixed to the top side via mounting hardware; the base tube connected to the modular stabilizing element providing support to the plurality of telescoping tubes. The modular stabilizing element, the top of the suitcase, or the entire suitcase with modular stabilizing element and base tube and telescoping handles may be manufactured as one unit by injection molding, cnc machining, or 3d additive manufacturing (3d printing), or other manufacturing process.. ... Biogen Inc

03/16/17 / #20170073393

Factor viii chimeric proteins and uses thereof

The present invention provides a chimeric protein comprising a first polypeptide which comprises a fviii protein and a first ig constant region or a portion thereof and a second polypeptide which comprises a vwf protein comprising the d′ domain and d3 domain of vwf, a xten sequence having less than 288 amino acids in length, and a second ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.. ... Biogen Inc

02/23/17 / #20170049904

Polyalkylene polymer compounds and uses thereof

The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis c.. ... Biogen Inc

02/16/17 / #20170044538

Compositions and methods for modulation of smn2 splicing in a subject

Disclosed herein are compounds, compositions and methods for modulating splicing of smn2 mrna in a subject.. . ... Biogen Inc

02/16/17 / #20170044512

Chimeric clotting factors

Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.. . ... Biogen Inc

02/09/17 / #20170037334

Systems and apparatus for production of high-carbon biogenic reagents

This invention provides processes and systems for converting biomass into highcarbon biogenic reagents that are suitable for a variety of commercial applications. Some embodiments employ pyrolysis in the presence of an inert gas to generate hot pyrolyzed solids, condensable vapors, and non-condensable gases, followed by separation of vapors and gases, and cooling of the hot pyrolyzed solids in the presence of the inert gas. ... Biogen Inc

02/09/17 / #20170037333

Process for producing high-carbon biogenic reagents

This invention provides processes and systems for converting biomass into high carbon biogenic reagents that are suitable for a variety of commercial applications. Some embodiments employ pyrolysis in the presence of an inert gas to generate hot pyrolyzed solids, condensable vapors, and non-condensable gases, followed by separation of vapors and gases, and cooling of the hot pyrolyzed solids in the presence of the inert gas. ... Biogen Inc

02/09/17 / #20170037140

Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

New combined therapeutic regimens for treatment of b-cell lymphomas are disclosed which comprise, in particular, administration of anti-cd20 antibodies to patients having low-, intermediate- or high-grade non-hodgkin's lymphomas.. . ... Biogen Inc

02/09/17 / #20170037139

Treatment of diffuse large-cell lymphoma with anti-cd20 antibody

The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-cd20 antibody and chemotherapy. Particular embodiments include the administration of anti-cd20 antibody in combination with chemotherapy comprising chop (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.. ... Biogen Inc

02/09/17 / #20170037126

Sp35 antibodies and uses thereof

Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. ... Biogen Inc

02/02/17 / #20170029859

Medium supplements for improved process performance

The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate.. ... Biogen Inc

02/02/17 / #20170029518

Anti-bcma antibodies

This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases.. ... Biogen Inc

01/26/17 / #20170022276

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. ... Biogen Inc

01/19/17 / #20170016919

Method of assessing risk of pml

The invention relates to methods of assessing a patient's risk of developing progressive multifocal leukoencephalopathy (pml).. . ... Biogen Inc

01/05/17 / #20170000873

Dimethyl fumarate and vaccination regimens

Provided herein is a method of treating or preventing a disease or disorder (e.g., ms) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., dmf) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.. . ... Biogen Inc

01/05/17 / #20170000100

Insect trap

The invention applies to an insect trap with a planar or curved, light-colored outflow surface for generating a weak airflow emanating from the outflow surface, with a device for holding, trapping, and/or killing the attracted insects, wherein at least one dark contrast spot is formed on the outflow surface. According to the invention, at least one device for increasing the attraction effect of the insect trap is arranged on the light-colored outflow surface, which device has a dark, sharp, in particular straight edge and/or corner and/or a dark, planar surface arranged at least largely vertically on the outflow surface.. ... Biogen Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Biogen Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Biogen Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###